Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial
Background Perforating artery territorial infarction (PAI) caused by branch atheromatous disease (BAD) is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen. Tirofiban, an adjunctive antiplatelet agent, has shown great potential to treat...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
|
| Series: | Stroke and Vascular Neurology |
| Online Access: | https://svn.bmj.com/content/early/2023/05/22/svn-2022-002284.full |
| _version_ | 1797821704263696384 |
|---|---|
| author | Liping Liu Yongjun Wang Yilong Wang Xingquan Zhao Xiaoling Liao Weiqi Chen Yuesong Pan Hui Qu Shuo Feng Yicong Wang |
| author_facet | Liping Liu Yongjun Wang Yilong Wang Xingquan Zhao Xiaoling Liao Weiqi Chen Yuesong Pan Hui Qu Shuo Feng Yicong Wang |
| author_sort | Liping Liu |
| collection | DOAJ |
| description | Background Perforating artery territorial infarction (PAI) caused by branch atheromatous disease (BAD) is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen. Tirofiban, an adjunctive antiplatelet agent, has shown great potential to treat acute ischaemic stroke. However, whether the combination of tirofiban and aspirin can improve the prognosis of PAI remains unclear.Aim To explore an effective and safe antiplatelet regimen for reducing the risk of recurrence and early neurological deterioration (END) in PAI caused by BAD by comparing the tirofiban and aspirin combination with placebo and aspirin combination.Methods Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY) trial is an ongoing multicentre, randomised, placebo-controlled trial in China. Eligible patients shall be randomly assigned to receive standard aspirin with tirofiban or placebo on the first day and standard aspirin from days 2 to 90. The primary endpoint is a new stroke or END within 90 days. The primary safety endpoint is severe or moderate bleeding within 90 days.Discussion The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with PAI.Trial registration number NCT05310968. |
| first_indexed | 2024-03-13T09:57:43Z |
| format | Article |
| id | doaj.art-779e4b7890604a709bba04fe135c98eb |
| institution | Directory Open Access Journal |
| issn | 2059-8696 |
| language | English |
| last_indexed | 2024-03-13T09:57:43Z |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Stroke and Vascular Neurology |
| spelling | doaj.art-779e4b7890604a709bba04fe135c98eb2023-05-23T15:30:07ZengBMJ Publishing GroupStroke and Vascular Neurology2059-869610.1136/svn-2022-002284Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trialLiping Liu0Yongjun Wang1Yilong Wang2Xingquan Zhao3Xiaoling Liao4Weiqi Chen5Yuesong Pan6Hui Qu7Shuo Feng8Yicong Wang9Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China1 Department of Neurology, Beijing Tiantan Hospital, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China1 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China3Peking University Health Science Center, Peking University Third Hospital, Beijing, ChinaDepartment of Biostatistics, School of Public Health, Brown University, Providence, Rhode Island, USADepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBackground Perforating artery territorial infarction (PAI) caused by branch atheromatous disease (BAD) is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen. Tirofiban, an adjunctive antiplatelet agent, has shown great potential to treat acute ischaemic stroke. However, whether the combination of tirofiban and aspirin can improve the prognosis of PAI remains unclear.Aim To explore an effective and safe antiplatelet regimen for reducing the risk of recurrence and early neurological deterioration (END) in PAI caused by BAD by comparing the tirofiban and aspirin combination with placebo and aspirin combination.Methods Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY) trial is an ongoing multicentre, randomised, placebo-controlled trial in China. Eligible patients shall be randomly assigned to receive standard aspirin with tirofiban or placebo on the first day and standard aspirin from days 2 to 90. The primary endpoint is a new stroke or END within 90 days. The primary safety endpoint is severe or moderate bleeding within 90 days.Discussion The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with PAI.Trial registration number NCT05310968.https://svn.bmj.com/content/early/2023/05/22/svn-2022-002284.full |
| spellingShingle | Liping Liu Yongjun Wang Yilong Wang Xingquan Zhao Xiaoling Liao Weiqi Chen Yuesong Pan Hui Qu Shuo Feng Yicong Wang Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial Stroke and Vascular Neurology |
| title | Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial |
| title_full | Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial |
| title_fullStr | Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial |
| title_full_unstemmed | Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial |
| title_short | Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial |
| title_sort | tirofiban combined with aspirin in the treatment of acute penetrating artery territory infarction strategy protocol for a multicentre randomised controlled trial |
| url | https://svn.bmj.com/content/early/2023/05/22/svn-2022-002284.full |
| work_keys_str_mv | AT lipingliu tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT yongjunwang tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT yilongwang tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT xingquanzhao tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT xiaolingliao tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT weiqichen tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT yuesongpan tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT huiqu tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT shuofeng tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial AT yicongwang tirofibancombinedwithaspirininthetreatmentofacutepenetratingarteryterritoryinfarctionstrategyprotocolforamulticentrerandomisedcontrolledtrial |